Orphan Drug Advantage Graphium has an FDA Orphan Drug Designation for VBX-100 aimed at pediatric ulcerative colitis, signaling strong regulatory support and potential market exclusivity that can be leveraged to secure partnerships, co-development deals, or milestone-based collaborations with pharma companies seeking GI inflammation assets.

Glycosylation Platform The proprietary glycosylation technology that attaches glucose to cannabinoids to modulate endocannabinoid effects presents a differentiated mechanism. This offers a sales angle to target biotech and pharma partners exploring non-psychoactive anti-inflammatory cannabinoids, potentially accelerating licensing or joint development talks.

Clinical Development Readiness A defined 3-year development plan for VBX-100 through remaining animal work and Phase I/II trials provides a tangible timeline for potential investors and collaborating sponsors, enabling BD teams to propose structured co-funding, milestone-based deals, or strategic acquisitions as milestones approach.

Public Funding Signals Public fundraising activity and investor relations milestones at Malachite Innovations indicate an ecosystem open to partnerships and financing for early-stage biotech assets, suggesting proactive outreach to strategic investors, family offices, and biotech-focused funds.

Market Opportunity Alignment Targeting a $20 billion inflammatory bowel disease market with a non-psychoactive, glycosylated cannabinoid positions Graphium to engage with GI specialists, academic consortia, and payer-focused alliances, highlighting opportunities for co-development, clinical collaboration, and value-based pricing conversations.